Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALLO), a clinical-stage biotechnology company ...

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $30.00.

Needham analyst Joseph Stringer maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s shares closed ...

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report)’s share price dropped 3.8% during trading on Friday . The stock traded as low as $10.81 and last traded at $10.78. Approximately 201,759 shares ...

Vir Biotechnology Inc (VIR) stock saw a modest uptick, ending the day at $11.2 which represents a slight increase of $0.67 or 6.36% from the prior close of $10.53. The stock opened at $10.48 and ...

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against the other ...

At the conference last week in San Francisco, pharmaphorum editor-in-chief Jonah Comstock spoke with Vir Biotechnology CEO ...

A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs ...

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six ...

With new legislation and noteworthy policies on sci-tech and innovation expected this year, businesses are hoping the right ...

China Medical University and Healthcare System hosted the International Forum of Extracellular Vesicles Technology and Novel ...